Shuttle Pharmaceuticals Holdings Inc Dossier
Qualitative Analysis
Business overview
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) is a specialty pharmaceutical company that has historically focused on improving outcomes for cancer patients treated with radiation therapy (RT). Founded in 2012 by faculty members of Georgetown University Medical Center, the company's initial therapeutic pipeline centered on developing small molecule radiation sensitizers, notably its lead candidate Ropidoxuridine (IPdR) for brain tumors such as glioblastoma. However, the company has undergone a profound strategic transformation. In late 2025, Shuttle Pharma acquired the assets of Molecule.ai, a Canadian artificial intelligence company specializing in molecular discovery, integrating machine learning and large language models into its drug discovery workflows. Concurrently, the company committed to winding down its clinical trials of Ropidoxuridine. In early 2026, Shuttle Pharma executed a highly unconventional pivot by merging with United Dogecoin Inc., transitioning its business model to encompass digital asset mining alongside its AI-driven molecular discovery platform.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Repositioning the company's business model by merging with United Dogecoin Inc. to build a large-scale Dogecoin and Litecoin mining operation, while holding mined coins as long-term treasury assets.
Expected impact: Expected to deliver up to approximately 43,200 GH/s of total hash rate once the initial 3,000 ElphaPex Scrypt mining rigs are fully deployed.
Integrating the acquired Molecule.ai software platform to leverage machine learning and large language models (LLMs) for molecular discovery and early-stage drug development.
Expected impact: Aims to shorten drug development timelines, reduce costs, and support drug-target interaction modeling through autonomous agentic AI workflows.
Deciding to wind down clinical trials of the lead drug candidate, Ropidoxuridine (IPdR), to preserve capital and realign resources toward the Molecule.ai platform and mining operations.
Expected impact: Reduces the high operational cash burn associated with running Phase II clinical trials.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To pivot the company's core business into Dogecoin and Litecoin mining, establishing a dual-track model that operates alongside the existing pharmaceutical software assets.
Financial impact: Funded via the issuance of 8,000 Series B-1 Convertible Preferred Shares (convertible into ~32.26 million common shares) and supported by a concurrent $9.55 million PIPE financing.
To enter the AI-driven drug discovery space and integrate an advanced software platform utilizing machine learning and LLMs for molecular evaluation and drug-target interaction modeling.
Financial impact: Acquired for an initial $8 million (combination of cash and stock) plus up to $2 million in contingent milestone-based payments.